• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.10% Nasdaq Up0.33%

    Genspera, Inc. (GNSZ)

    -Other OTC
    0.13 Down 0.01(5.66%) 10:05AM EDT
    ProfileGet Profile for:
    Genspera, Inc.
    2511 North Loop 1604 West
    Suite 204
    San Antonio, TX 78258
    United States - Map
    Phone: 210-479-8112
    Fax: 210-479-8113
    Website: http://www.genspera.com

    Index Membership:N/A
    Full Time Employees:1

    Business Summary 

    GenSpera Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States. It develops cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, and other cancers. The company’s prodrug development candidates comprise Mipsagargin, a prostate specific membrane antigen that is in Phase II clinical trial for the blood vessels of various solid tumors; G-115, a prostate specific antigen, which has completed pilot toxicology, as well as limited pre-clinical development stage for the treatment of prostate cancers; G-114, a prostate specific antigen for treating prostate cancers; and G-301, a human glandular kallikrein 2 for the treatment of prostate cancers. GenSpera Inc. was founded in 2003 and is based in San Antonio, Texas.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Genspera, Inc.

    Key Executives 
    Dr. Russell B. Richerson Ph.D., 64
    Interim Principal Exec. Officer, Chief Operating Officer, Interim Principal Accounting Officer and Sec.
    Dr. John T. Isaacs Ph.D.,
    Co-Founder, Chairman of Scientific Advisory Board and Chief Scientific Advisor
    Dr. Samuel R. Denmeade M.D.,
    Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders